| Bioactivity | (Rac)-BDA-366 (example 2) is the despinner of BDA-366 (HY-101083). BDA-366 is a potent Bcl-2 antagonist (Ki=3.3 nM), binding Bcl-2-BH4 domain with high affinity and selectivity. BDA-366 induces conformational change in Bcl-2 that abrogates its antiapoptotic function, converting it from a survival molecule to a cell death inducer. BDA-366 suppresses growth of lung cancer cells[1][2]. |
| Name | (Rac)-BDA-366 |
| CAS | 142645-19-0 |
| Formula | C24H29N3O4 |
| Molar Mass | 423.50 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Spinx Pharmaceuticals Corp. Preparation of bis(hydroxyalkylamino) anthraquinones as protein kinase C inhibitors. World Intellectual Property Organization, WO9207557 A1 1992-05-14 [2]. Han B, Park D, Li R, et al. Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy. Cancer Cell. 2015;27(6):852-863. |
(Rac)-BDA-366
CAS: 142645-19-0 F: C24H29N3O4 W: 423.50
(Rac)-BDA-366 (example 2) is the despinner of BDA-366 (HY-101083). BDA-366 is a potent Bcl-2 antagonist (Ki=3.3 nM), bin
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.